PT  - JOURNAL ARTICLE
AU  - Gordon, Debra
ED  - Brown, Jacques
TI  - Long-Term Safety and Efficacy of Denosumab in Postmenopausal Osteoporosis
DP  - 2011  01
TA  - MD Conference Express
PG  - 12--12
VI  - 11
IP  - 13
4099  - http://mdc.sagepub.com/content/11/13/12.short
4100  - http://mdc.sagepub.com/content/11/13/12.full
AB  - The efficacy and safety of the antiresorptive agent denosumab on bone mineral density and fracture rates were assessed in an open-label extension, crossover trial of the original 3-year, randomized, placebo-controlled Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months study. [FREEDOM; NCT00089791; Cummings SR et al. N Engl J Med 2009].